Oral Paclitaxel combination regimen has graduated from this Phase 2 trial in the triple negative breast cancer subgroup of the I-SPY2 Trial
Oral Paclitaxel combination regimen has graduated from this Phase 2 trial in the triple negative breast cancer subgroup of the I-SPY2 Trial
Keytruda's recent success in TN breast cancer predicted by I-SPY2 results
Come see what I-SPY has been up to at the 2018 San Antonio Breast Cancer Symposium
Video available of the I-SPY press event held September 12, 2018.
Dynavax Technologies Corporation and Quantum Leap Healthcare Collaborative™ announced that Dynavax’s SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in the I-SPY 2 TRIAL